{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001422","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2025-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.979536+00:00","generated_at":"2026-05-24T22:04:44.202663+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Harvard Bioscience Q4 revenue $24.6M, FY 2024 net loss widens to $12.4M","bullets":["Q4 2024 revenue $24.6M, down 12.8% from $28.2M in Q4 2023.","Full-year 2024 revenue $94.1M vs $112.3M; net loss $(12.4)M vs $(3.4)M.","Adjusted EBITDA fell to $7.2M from $14.6M; operating cash flow dropped to $1.4M from $14.0M.","CEO cites challenging market; highlights SoHo telemetry and MeshMEA organoid systems as growth drivers.","Q4 net income was $18K vs loss of $(1.8)M in Q4 2023 (slight improvement in quarter)."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001422","json":"https://secwatch.observer/filing/0001171843-25-001422.json","markdown":"https://secwatch.observer/filing/0001171843-25-001422.md","text":"https://secwatch.observer/filing/0001171843-25-001422.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325001422/0001171843-25-001422-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325001422/f8k_031225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T22:04:44.202663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}